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Objective: Smoking cue-(SC) elicited craving can lead to relapse in SC-vulnerable individuals. Thus, identifying treatments that target SC-elicited craving is a top research priority. Reduced drug cue neural activity is associated with
recovery and is marked by a profile of greater tonic (resting) activation in executive control regions, and increased
connectivity between executive and salience regions. Evidence suggests the GABA-B agonist baclofen can reduce drug
cue-elicited neural activity, potentially through its actions on the resting brain. Based on the literature, we hypothesize
that baclofen’s effects in the resting brain can predict its effects during SC exposure.
Methods: In this longitudinal, double blind, placebo-controlled neuropharmacological study 43 non-abstinent, sated
treatment-seeking cigarette smokers (63% male) participated in an fMRI resting-state scan and a SC-reactivity task prior
to (T1) and 3 weeks following randomization (T2; baclofen: 80 mg/day; n = 21). Subjective craving reports were acquired before and after SC exposure to explicitly examine SC-induced craving.
Results: Whole-brain full-factorial analysis revealed a group-by-time interaction with greater resting brain activation of
the right dorsolateral prefrontal cortex (dlPFC) at T2 in the baclofen group (BAC) (p FWEcorr = 0.02), which was associated
with reduced neural responses to SCs in key cue-reactive brain regions; the anterior ventral insula and ventromedial
prefrontal cortex (p FWEcorr ＜ 0.01). BAC, but not the placebo group reported decreased SC-elicited craving (p = 0.02).
Conclusion: Results suggest that baclofen mitigates the reward response to SCs through an increase in tonic activation
of the dlPFC, an executive control region. Through these mechanisms, baclofen may offer SC-vulnerable smokers protection from SC-induced relapse.
KEY WORDS: Baclofen; Cerebral blood flow; Cue-elicited craving; Nicotine; Perfusion fMRI; Resting-state.

INTRODUCTION

half of those who have made a quit attempt will relapse
within a year [3]. Because of the myriad caveats associated with the study of real-world smoking, the role of
smoking cue (SC) exposure in relapse remains equivocal
[4]. However, SC-elicited craving persists as a key metric
by which to assess the severity of nicotine use disorder because cues elicit conditioned responses such as craving
and approach behavior [5-7]. Further, former smokers
continue to view SCs as salient long after cessation, and
often cite SC exposure as their reason for relapse [8].
SCs increase neural activity in reward-related brain regions, independent of pharmacological withdrawal [9],
SC-induced craving can predict increased smoking behavior [10], and SC-elicited neural activation in reward

The consequences of smoking are devastating, yet approximately 20% of the world’s population above the age
of 14 continues to smoke [1]. Although smokers indicate
that they want to quit, success rates are low [2], and over
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regions can predict relapse [11]. Furthermore, decreased
functional connectivity between a salience region (anterior
ventral insula; avInsula) and an executive control region
(the dorsolateral prefrontal cortex; dlPFC) during SC exposure predicts relapse, indicating that decoupling of salience and executive control regions contribute to SC vulnerability [12]. Similarly, smokers with greater response
in reward regions during SC exposure have greater difficulty quitting smoking [13]. Collectively, these studies
elucidate a select role of SC vulnerability in relapse.
The primary smoking cessation medications are nicotine replacement therapy, bupropion, and varenicline,
all three of which reduce withdrawal from nicotine [14].
Varenicline, the most effective and most commonly prescribed, has a second mechanism: before cessation, it
blocks nicotine’s reinforcing effects [15,16]. Nonetheless,
varenicline does not help most individuals to whom it is
prescribed, as relapse rates remain high [17]. In line with
varenicline’s mechanism, varenicline-responders could
represent a subgroup of smokers whose vulnerability to
relapse is coupled with nicotine reinforcement, while
those who do not respond to varenicline may have unmet
vulnerabilities such as those associated with SC exposure.
Currently, there are no medications directly targeting SC
reactivity to aid SC-vulnerable individuals.
GABA-B agonists inhibit dopaminergic afferents in reward regions, including nicotine-induced reward signaling [18]. There is substantial evidence that the GABA-B
agonist baclofen blocks conditioned drug-related behaviors and may target drug cue vulnerabilities in humans
[19-22]. One functional magnetic resonance imaging (fMRI)
study showed that baclofen reduced reward-related neural
responses to cocaine cues in abstinent, treatment-seeking
cocaine participants, however baclofen-induced changes
from baseline could not be determined from that study
[23]. Another recent neuropharmacological study examined baclofen’s effects on alcohol cue reactivity in abstinent alcohol use disorder (AUD) treatment-seeking patients relapse [24]. Authors examined cue reactivity prior
to and after two weeks of medication. Baclofen increased
activity of the anterior cingulate cortex (ACC) and bilateral dlPFC while decreasing responses in the ventral
striatum (VS) and orbitofrontal and insular cortices. Responses
in the ACC and insula predicted time to relapse [24].
Collectively, these studies suggest a common mechanism
whereby baclofen blunts the neural response to drug

cues, which could be a useful/necessary mechanism of
blunting cue-induced craving in cue-vulnerable substance use disorder patients.
Using the quantitative technique of perfusion fMRI, we
have shown that baclofen increases cerebral blood flow
(CBF) in executive control regions, including the dlPFC
and ACC, in the resting brain and blunts CBF in reward regions, suggesting tonic modulation of the brain at rest
[25]. Greater tonic activation of executive control regions, as operationalized by resting state neuroimaging,
could be an indicator of nicotine use disorder improvement: greater tonic executive control may be necessary to
avoid a lapse when encountering SCs [26-28].
In the present study, we seek to extend the findings of
ourselves and others by determining whether baclofen-related changes in the resting brain are associated with
SC-reactivity within cigarette smokers. Based on our previous findings and those of Holla et al. [24], 2018 and
Janes et al. [12], 2010, described above, we hypothesized
(1) that baclofen would increase CBF in the bilateral
dlPFC and the ACC in the resting brain, and (2) that the increases observed in resting CBF would be associated with
decreases in CBF during SC exposure in our a priori reward regions (i.e., ventromedial prefrontal cortex/medial
orbitofrontal cortex [vmPFC/mOFC], VS, and avInsula)
[9,11,12,24,29,30].

METHODS
All procedures were conducted at the University of
Pennsylvania Center for Studies of Addiction. All procedures were approved by the University of Pennsylvania’s
Institutional review board (IRB No. 817101) and conducted in accordance with the Declaration of Helsinki.
All participants provided written informed consent. This
study was pre-registered at ClinicalTrials.gov, with Identifier:
NCT01821560.

Participants
Participants were treatment-seeking cigarette smokers,
18−60 years old, who smoked at least 10 cigarettes per
day (CPD) for the past 6 months. Interested volunteers
were recruited by flyers, listservs, and word of mouth and
completed an initial phone screen and, if eligible, an
in-person consent and screening visit. After providing informed consent, participants completed the Fagerström
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Test for Nicotine Dependence (FTND) [31] and underwent physical and psychiatric screening. Physical screening included a blood test to ensure general physical
health, an EKG, a urine toxicology test to rule out the presence of psychoactive drugs, and a pregnancy test in
females. Psychological screening ascertained any current
severe psychiatric symptoms, or diagnosis of any substance use disorders (SUDs) other than nicotine (MINI;
[32]). Participants were excluded for current other SUDs,
current Axis 1 DSM-IV disorder, an intellectual ability estimate score below 80 [33], use of any other smoking cessation strategies, and any MRI contraindications [34].
Potential contraindications were reviewed by the study
physician, and participants were financially compensated
for participation. Participants were randomized to receive
either baclofen or placebo after their first MRI scan. The
study design is illustrated in Figure 1.
Twenty-three baclofen recipients (BAC) and 22 placebo recipients (PBO) completed study procedures. One
participant was excluded for abnormally large ventricles
and one participant was excluded for insufficient signal-to-noise ratio in their resting-state data.
Subjective craving scores were excluded for two baclofen participants based on an error in assessment administration. Analyses were completed on the remaining 21

BAC and 22 PBO, except the SC-elicited craving analyses
which included 19 BAC and 22 PBO. Participant characteristics are listed in Table 1.

Medication
Study medication was manufactured and provided by
Murty Pharmaceuticals, Inc., Lexington, KY, USA. The
Investigational Drug Service at the University of Pennsylvania maintained and distributed medication in blister
packs (randomized by medication group and sex). All
study staff and participants were blinded to the medication administered. A nurse practitioner met with participants weekly to collect used pill packs (compensation
was provided to encourage adherence), distribute new
packs, and monitor adverse events and medication adherence/issues. The most common adverse event reported for
baclofen is drowsiness. Based on pilot data conducted in
our lab, we were able to accelerate the titration schedule
used in our previous study [25] without affecting side effects, including drowsiness. Similarly to Logge et al. [22],
2019, we used a titration schedule wherein participants
reached the full dose of 80 mg (20 mg q.i.d.) by day 4
(Table 2).

Fig. 1. Study design. Participants underwent a double-blind, placebo-controlled study in which they received 20 mg q.i.d. baclofen or placebo.
They participated in a functional magnetic resonance imaging (fMRI) session before randomization (T1), and a second session after three weeks of
treatment (T2). At each session, one of two similarly valanced smoking cue (SC) and non-SC sets was presented in a pseudorandomized fashion to
control for habituation.
p CASL, pseudo-continuous arterial-spin labeled; MPRAGE, magnetization-prepared rapid gradient echo.
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Table 1. Demographics and smoking characteristics
Variable
Sex, male
Age
IQ
Race
African American
Caucasian
Asian
Ethnicity
Hispanic
Education
Alcohol use
Endorsed use
a
Drinks per drinking day, T1
Cannabis use
Endorsed use
a
Days of cannabis use, T1
Smoking characteristics
FTND
Pack years
CPD
T1
T2

Baclofen (n = 21)

Placebo (n = 22)

13 (62)
38.9 ± 12
97.4 ± 12.1

Group comparisons
2

t or 

p value

14 (64)
40.2 ± 12
103.8 ± 12.4

0.01
−0.47
−1.64

0.91
0.64
0.11

12 (55)
7 (33)
2 (10)

14 (64)
6 (27)
2 (9)

0.19
0.19
＜ 0.01

0.66
0.67
0.96

1 (0.1)
13.3 ± 1.8

3 (0.1)
14 ± 1.8

＜ 0.01
−1.06

1.0
0.29

12 (50)
2.7 ± 2.10

13 (59.1)
3.1 ± 2.4

0.02
0.46

0.87
0.65

7 (31.8)
5 ± 2.6

8 (36.4)
4.5 ± 2.4

＜ 0.01
0.23

1.0
0.82

4.9 ± 1.5
16.6 ± 13.8

4.9 ± 1.5
15.6 ± 12.6

0.19
0.23

0.85
0.82

14.4 ± 5.7
12.9 ± 7.5

13.9 ± 4.8
9.5 ± 4.7

0.35
1.72

0.73
0.09

Values are presented as number (%) or mean ± standard deviation.
T1, before treatment; T2, on medication and after 3 weeks of treatment; FTND, Fagerström Test for Nicotine Dependence; CPD, cigarettes per day.
a
In participants who used this substance in the last 30 days, measured by the Timeline Follow Back. There were no differences between groups in
any demographics or smoking characteristics.

Table 2. Baclofen titration schedule
Study day

8:00 AM

12:00 PM

4:00 PM

8:00 PM

Day 1
Day 2
Day 3
Day 4−7
Week 2−7
Week 8 Day 1−2
Week 8 Day 3−4
Week 8 Day 5−6
Week 8 Day 7

PBO
PBO
PBO
20 BAC
20 BAC
PBO
PBO
PBO
PBO

10 BAC
10 BAC
20 BAC
20 BAC
20 BAC
20 BAC
20 BAC
10 BAC
PBO

PBO
10 BAC
20 BAC
20 BAC
20 BAC
20 BAC
PBO
PBO
PBO

10 BAC
10 BAC
20 BAC
20 BAC
20 BAC
20 BAC
20 BAC
10 BAC
PBO

Baclofen (BAC) was titrated up to full dose (week 1) and tapered
down (week 8) to mitigate adverse effects, including drowsiness.
Placebo medication (PBO) was used to ensure blinding during the
titration process.

Study Design
To determine the effect of baclofen on neural function
and SC-elicited craving, we used a double-blind, placebo-controlled paradigm. At baseline, participants and
study staff agreed upon a “Quit Date” on which participants would attempt to quit smoking. Importantly, this

occurred after the second scan (Time 2, T2) to mitigate
any effects of quitting smoking on brain endpoints.
Participants were instructed to continue smoking as usual
until their Quit Date. Participants began the medication
regimen after their first scan (Time 1, T1). After three
weeks of treatment, participants underwent a second perfusion fMRI scan session following the same scan protocol
(T2). CPD were recorded at both timepoints. Participants
then returned for their “Quit Week” appointment, at
which time they received smoking cessation counseling
and continued treatment for four additional weeks (Fig. 1).
All MRI sessions occurred in the early afternoon, to
minimize any confounding effects of time of day, or effects of participants’ daily routines on study results [35].
fMRI sessions included a pseudo-continuous arterial-spin
labeled (p CASL) perfusion fMRI scan at rest and during a
SC reactivity task. p CASL is an MRI tool providing an objective measure of neural activity, using magnetically tagged blood as an inherent tracer [36]. Unlike blood oxygen
level-dependent fMRI, perfusion fMRI is quantitative, pro-
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viding a measure of blood flow measured in milliliters of
blood/100 g of tissue/minute. This gives perfusion fMRI
the unique advantage of providing a baseline measurement, and as such, it is ideal for studying the effect of
pharmacological agents on neural activity [36]. Furthermore, perfusion fMRI is particularly suited for longitudinal
studies, as it is reliable and replicable for up to seven
weeks [37]. Finally, the quantitative technique of perfusion fMRI is ideal for measuring states that accrue slowly
over time, such as craving generated by drug cues.
Additionally, craving may persist after stimulus exposure,
often extinguished only by smoking, thus perfusion fMRI
is well-suited to our model in which stimuli are presented
over several minutes.
At both timepoints, participants were non-abstinent to
minimize potential confounds introduced by withdrawal
and to minimize differences between groups in smoking
behavior, both of which might affect neural responses.
Participants smoked ad libitum throughout the day of their
scan, and smoked one of their own cigarettes to satiety (ad
libitum) approximately 25 minutes before data acquisition to minimize the influence of smoking on vasculature
[38], which affects blood flow in the brain. Baclofen has a
short half-life (approximately 4 hours), thus participants
took their medication (20 mg baclofen or matching placebo) 1−1.5 hours prior to the T2 session in the presence of
study staff to ensure medication compliance and standardize dose time. To minimize “carryover” effects in neural response to SCs, non-SCs were presented before SCs
[39]. While it is customary in some paradigms to counterbalance stimuli across scans and across participants to
minimize a confounding effect of stimulus order in the results, we have previously established that (1) order effects
are negligible [9], and (2) such counterbalancing can introduce a “carryover” effect in responses, as craving elicited by SCs, when presented first, are not completely extinguished by the time non-SCs are subsequently presented [39]. Participants completed the Craving and
Withdrawal Questionnaire (CWQ) to assess SC-elicited
changes in craving and withdrawal before and immediately after the SC task [9,40].

ing-related or nonsmoking-related cues. Unlike BOLD
fMRI, perfusion MRI provides an objective measurement
of blood flow, which precludes the need for counterbalancing. As such, the non-SC video was presented before the SC video, to prevent carryover effects. To prevent
practice effects, participants saw one of two similarly valanced SC and non-SC videos at their first scan, and the
second set of videos at their second scan. The order of
presentation of videos was pseudorandomized across
subjects. The SC videos featured actors smoking, while
using language explicitly designed to induce desire for a
cigarette (e.g., “The cigarette I enjoy most is the first cigarette of the day”). The non-SC videos featured actors, but
they were not smoking, and instead, told short stories unrelated to smoking and without smoking reminders.
During the SC videos, subjects held one of their own cigarettes in their preferred hand, and a match was lit and extinguished, providing visual and olfactory stimuli to enhance neurophysiological and subjective cue reactivity.
During the non-SC video, subjects held a freshly sharpened pencil.

fMRI Stimuli
Stimuli presented during the non-SC and SC scans comprised audiovisual clips, each nine minutes long, featuring actors differing in race, age, and sex, and either smok-

Imaging Data Preprocessing
We performed image processing using Statistical Parametric Mapping 12 (SPM12, the FIL Methods Group, 2016),
ASL toolbox [41], Functional MRI of the Brain Software

Scan Protocol and Parameters
MRI scanning occurred on a Siemens 3.0 Tesla Trio
whole-body scanner (Siemens AG, Erlangen, Germany),
using a standard Transmit/Receive head coil. High resolution MR images were acquired using T1-weighted 3D
magnetization-prepared rapid gradient echo (MPRAGE)
scan (TR/TE/TI = 1,620/3/950 ms, flip angle = 90°, band3
width = 150, voxel size = 1 mm , matrix = 192 × 256, slices = 160). Two-dimensional p CASL perfusion fMRI was
used to acquire resting baseline, SC, and non-SC scans.
The resting scan protocol included 45 resting label/control image pairs (labeling time, 1.5 seconds; post-labeling
delay, 1,000 ms; matrix, 64 × 64 × 18; flip angle, 90°; TR,
3.5 seconds; TE, 17 ms; slice thickness, 7.2 mm; voxel
size = 3.44 × 3.44 × 7.2 mm). The SC and non-SC scan
protocols each included 68 cue label/control image pairs
(labeling time, 1.5 seconds; post-labeling delay, 1,500 ms;
matrix, 64 × 64 × 18; flip angle, 90°; TR, 4 s; TE, 17 ms;
slice thickness, 7.2 mm; voxel size = 3.44 × 3.44 × 7.2 mm).
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Library [42] and custom scripts in MATLAB 2016a [43].
Prior to the analyses, brain images were visually inspected for gross movement, structural abnormalities and
whole brain coverage. Each participant’s anatomical and
ASL images were manually reoriented to the anterior/posterior commissure line (AC-PC line), to improve segmentation and normalization accuracy. The raw echoplanar
imaging images were then realigned to correct for head
motion using the method proposed by Wang [44]. The
mean ASL image was aligned to the anatomical image of
each subject using the FSL Boundary Based Registration
(BBR) approach [45]. Using SPM, the anatomical image of
each subject was probabilistically segmented into grey
matter, white matter and cerebrospinal fluid to construct a
binary brain mask [46]. The brain mask was down-sampled to the MNI space using the BBR co-registration parameters, and was used to restrict the CBF computation
within the mask. Thereafter, a CBF time series was obtained by pairwise control-label subtraction, normalizing
by corresponding control image, and using a single compartment model with recommended parameters [47].

Image Quality Control Assessment
A mean CBF map was obtained using a Structural
Correlation with Robust Bayesian (SCRUB) estimation approach [48,49] to remove artifacts from ASL-CBF images.
The quality of mean CBF maps for each subject was evaluated using an automated quality evaluation index (QEI)
[50], with output values between 0 (no signal) and 1
(highest signal). A QEI of 0.7 or above demonstrates high
sensitivity-specificity, and thus was our criterion for inclusion in analyses. The anatomical images were normalized to the MNI space using FSL non-linear registration
and this, coupled with the BBR transformation, was used
to normalize the CBF maps to the MNI space. The normalized CBF maps were thereafter smoothed with a 5mm full
width at half maximum Gaussian kernel. For group level
analyses, each model included a global calculation of the
mean voxel value within the image as a regressor of no interest for data normalization.
Demographics and Behavior Analyses
We conducted all demographics and behavior analyses
in R version 3.4.2 (https://www.r-project.org/) [51]. Before,
and immediately after viewing SCs, participants were verbally administered the CWQ, which included a question

to probe craving: “On a scale of 1−7, with 7 as the highest and 1 as the lowest rating, how much do you crave a
cigarette right now?” We calculated a change score for
subjective craving (post-SC−pre-SC) such that a positive
score indicates an increase in craving. We analyzed participants’ responses using linear mixed models, in which
subjective craving rating was the dependent variable, and
group (BAC or PBO), timepoint (T1 or T2), and rating time
(pre- or post-SC exposure) were included as fixed independent variables [52]. We included participant ID as a
random variable to provide each individual’s intercept.
The primary result of interest was a group-by-week-bypre-/post-cue exposure interaction. We also examined
each group separately via post-hoc paired t tests to determine potential differences between T1 and T2 SC-elicited craving.

Imaging Analyses
As in our previous work, all analyses included participants’ sex and age as nuisance covariates. No other demographic or smoking characteristics were included in the
model as there were no differences between groups in any
relevant variables (Table 1). All results reported in a priori
regions of interest (ROIs) were small-volume corrected
(SVC) with a 5 mm radius around the previously identified
clusters [9,25] and passed family-wise-error (FWE) correction, as well as a Šidák correction for multiple comparisons [53,54] at a statistical threshold of p ＜ 0.01. We
used R and MANGO (http://ric.uthscsa.edu/mango/mango.html) [55] to generate figures.
For hypothesis 1, that baclofen would increase CBF in
cognitive control regions at rest, all participant’s mean
resting images were included in a full factorial analysis, to
determine a group-by-timepoint interaction. Based on the
literature, ROIs for examining the effects of baclofen on
the resting brain were the ACC (−8, −14, 40) and right
and left dlPFC (±51, 24, 33) [12,24,25].
For hypothesis 2, that the baclofen-induced increase in
ROIs at rest would be associated with a decrease in the reward response during SC-exposure, we calculated a
change value from the resting data (T2-T1) in the ROIs and
entered them independently as covariates in the SC-model at T2, as previously described [26]. Based on the literature and our significant experience examining the brain
substrates of SC-induced brain activity, ROIs included the
VS, vmPFC, and avInsula [9,24,29,56,57].
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RESULTS
Participant Characteristics
There were no differences in age, sex, race, ethnicity,
education, IQ, FTND scores, CPD, pack years, or canna-

bis and alcohol use between BAC and PBO recipients
(Table 1). A linear mixed model revealed an overall effect
of CPD between the groups and timepoints, F(3,81) =
3.05, p = 0.033. However, there were no effects of timepoint  = −1.57, standard error (SE) = 1.78, p = 0.38,
group  = 2.20, SE = 3.95, p = 0.58, or the interaction between group and timepoint,  = −2.77, SE = 2.50, p =
0.27.

Adverse Events
There were no differences between BAC and PBO
groups in total number of adverse events t(33) = 1.56, p =
0.13, d = 0.48. Because sedation, or “drowsiness,” is the
adverse effect most commonly associated with baclofen,
we examined it separately. There was no difference between groups in sedation, t(36) = 1.32, p = 0.20, d = 0.42.
Fig. 2. Smoking cue-elicited craving before and after 3-weeks of
medication. Participants were asked how much they craved a cigarette
before and after seeing smoking cues. Smoking cue-induced craving
scores were calculated by subtracting pre-session ratings from postsmoking cue (SC) ratings at each timepoint. Baclofen, but not placebo
participants reduce SC-elicited craving from pretreatment (T1) to
during treatment (T2). Translucent bars indicate 95% confidence
intervals.

Smoking Cue-elicited Craving
Two participants’ SC-elicited craving data were missing.
Of the remaining participants, a linear mixed model revealed an overall effect, F(3,78) = 2.95, p = 0.038. There
was an effect of timepoint,  = −1.32, SE = 0.49, p ＜
0.01, no effect of group,  = −1.59, SE = 1.07, p = 0.14,

Fig. 3. The effects of baclofen on
dorsolateral prefrontal cortex (dlPFC)
in the Brain at Rest Predict responses
to smoking cues (SCs). (A) Coronal,
axial, sagittal, and 3D images showing
a baclofen-induced increase in right
dlPFC cerebral blood flow (CBF) in
the brain at rest, Z = 2.95, p = 0.021.
(B) The dlPFC increase in the brain at
rest predicted a decrease in the neural
response to SCs in the ventral medial
prefrontal cortex, Z = 4.33, pFWEcorr =
0.002 (top 3D image) and the left
ventral anterior insula, Z = 3.85,
pFWEcorr = 0.002 (bottom 3D image).
Coordinates are in MNI space. Clusters
are defined via whole-brain voxelwise analysis. Values are family-wise
error (FWE) corrected.
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and an interaction effect between timepoint and group  =
1.36, SE = 0.68, p = 0.047. Post-hoc t tests revealed that
this effect was driven by a reduction in SC-elicited craving
in baclofen participants from T1 to T2, t = 2.90, p ＜ 0.01
(Fig. 2), whereas there was no change in placebo participants between timepoints, t = −0.09, p = 0.93.

Imaging Results
All imaging results can be viewed in detail at
ArielKetcherside.com. For our first hypothesis, that baclofen would increase resting brain activity in cognitive control regions, we performed a full factorial model in
SPM12. This showed a timepoint-by-group interaction
such that BAC participants had greater resting activation
in the right dlPFC at T2 and compared to PBO (Z = 2.78,
SVC p FWEcorr = 0.03, Fig. 3A, see S1 for boxplot). There
was no effect of timepoint on resting state CBF in our other
ROIs, the ACC or the left dlPFC in BAC.
Given our second hypothesis, that baclofen-induced
change in CBF within our ROIs at rest would associate
with a decrease in the reward response during SC exposure, we extracted the values from the ROI wherein we
saw an effect, the right dlPFC (calculated as T2-T1) and
used them as covariates in the SC T2 model, as previously
described [26]. We found that the baclofen-induced increase in right dlPFC at rest was associated with a decrease in neural response in the vmPFC (Z = 4.33, p FWEcorr =
0.002) and left avInsula (Z = 3.85, SVC p FWEcorr = 0.002)
during SC exposure (Fig. 3B).

Post-hoc Brain-behavior Correlations
We performed a post-hoc analysis to determine if baclofen-induced changes in neural response to SCs correlated with subjective reports of SC-induced craving. First,
we performed a full factorial analysis to identify a stimulus
(SCs and non-SCs)-by-timepoint (T1 and T2) interaction
effect on neural changes in SC response during treatment
in both the baclofen and placebo groups. We then extracted the average value from a 5 mm sphere surrounding the peak voxel of the SC ROIs and examined whether
these values correlated with the magnitude of change in
SC-induced ratings for craving from T1 to T2. We observed a trend toward correlation between the magnitude
of the decrease in SC-craving and the magnitude of the
decrease in the left avInsula from T1 to T2 (−38, 14, −16),
r = 0.36, p = 0.06 and in the vmPFC (4, 22, −14), r = 0.35,
p = 0.07, the two regions previously identified in our testing of hypothesis 2. While these do not pass the
“bright-line fallacy” threshold of significance [58], or the
Šidák correction for multiple comparisons that would be
most prudent for interpretation as stand-alone results
(p adjusted ＜ 0.03) [53,54,59], we present them here for interpretation in the context of our overall results. While further examination is necessary, these preliminary findings
suggest that, the more BAC participants exhibited reduced
activation in limbic regions, which have been shown
throughout the literature to be associated with craving,
the less SC-craving they reported (Fig. 4). The same analysis in PBO participants showed no correlations.

Fig. 4. Baclofen’s effects on brain response to SCs trends toward correlation with SC-elicited craving. (A) The magnitude of decrease in SC-induced
craving (T2-T1) trended toward correlation with the magnitude of decrease in left avInsula activation (T2-T1), MNI coordinates (−38, 14, −16), r =
0.36, p = 0.06, as well as (B) the magnitude of decrease in the vmPFC, MNI coordinates (4, 22, −14), r = 0.35, p = 0.07.
SC, smoking cue; T1, before baclofen; T2, during treatment with baclofen; avInsula, anterior ventral insula; vmPFC, ventromedial prefrontal cortex.
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Additional post-hoc analyses on this data set are provided at ArielKetcherside.com.

DISCUSSION
We examined baclofen’s effects on the resting brain in
a priori cognitive control regions (ACC and dlPFC) and relationships between baclofen-induced resting changes
and response to SCs in reward regions (vmPFC, VS,
avInsula). Results indicate that baclofen increased resting
right dlPFC activation, which was associated with a decrease in left avInsula and vmPFC SC-elicited activation.
Further, while both groups reported SC-elicited craving
prior to medication (T1), only baclofen-treated subjects
showed reduced SC-elicited craving during treatment
(T2). Our findings align well with those of Holla and colleagues [24] who showed that baclofen increased activity
in the dlPFC and decreased activity in the insula in AUD
patients during alcohol cue exposure that subsequently
predicted time to relapse, suggesting a common mechanism for mitigating craving across substances of abuse.
Our finding that baclofen increased dlPFC activation at
rest replicates our previous findings [25] and is consistent
with literature implicating the dlPFC in recovery from substance use disorders [24,60-62]. The prevailing theory
uniting these studies postulates that increased resting activity in the dlPFC can improve individuals’ ability to mitigate conditioned responses that lead to relapse. The
dlPFC is a hub of inhibitory control within the executive
control network [63], and during SC-reactivity, it integrates cue perception, craving, and behavior planning
to seek or avoid SCs [64]. Thus, the baclofen-induced increase in resting dlPFC observed here could indicate a
similar increase in tonic executive control, enabling participants to self-regulate reactivity to SCs.
When included as a covariate in the model assessing
SC-reactivity, the BAC-induced increase in resting dlPFC
activation predicted a decrease in left avInsula activity in
response to SCs, indicating that, the greater the tonic
dlPFC activation, the less the avInsula responded to SCs.
The insula integrates sensory, salience, and executive
control networks, and the avInsula is associated with subjective “urge” for drugs in response to drug cues
[9,29,64-68]. Janes et al. have shown that avInsula activation in response to SCs predicted relapse during subsequent smoking cessation attempts [11,12] and that de-

creased anterior insula-dlPFC functional connectivity during SC exposure predicts relapse [12]. In line with this
work, our findings suggest that the greater the tonic activation of the dlPFC, the less the avInsula responds to SCs,
which could potentially prevent relapse. Associations between the left avInsula and craving have been observed
repeatedly in the SC literature, however the right insula
has also been implicated, and thus the laterality of our results should be addressed [11,12]. One such explanation
lies in previous work suggesting that the left avInsula responds more to positive stimuli than the right [69]. As our
SCs are highly appetitive, the left avInsula may have been
more engaged during SC exposure prior to medication,
such that baclofen’s effects are observable to a greater extent on the left side. Baclofen’s modulation of the dlPFC
was also associated with a decrease in vmPFC response to
SCs. This is congruent with literature showing that vmPFC
activation during SC exposure is associated with craving,
while its reduced activity is associated with smoking cessation interventions and reduced craving [26,30,70].
Collectively, results suggest a mechanism by which baclofen may blunt SC-responsivity, and thereby prevent
SC-induced relapse.
Additionally, post-hoc analyses in baclofen participants
showed that the magnitude of baclofen-induced decreases in neural response to SCs in the avInsula and
vmPFC (T1-T2) trended toward correlation with the magnitude of the decrease in subjective reports of SC-induced
craving (T1-T2). In other words, the more BAC participants exhibited reduced activation in limbic regions,
which have been established within the literature as
mechanisms of craving, the less SC-craving they reported.
While these correlations were small and only trended toward statistical significance, we note that patterns in the
data are notable, given the small range of possible answers to the craving questionnaire (1−7) and the ensuing
double subtraction of the scores. Given that these results
link our imaging and behavioral findings, they further support our hypothesis for the proposed mechanism of baclofen in SC-craving reduction. Furthermore, they are similar
to our previous results [26]. As such, this relationship
should be examined further in future work with a more
sensitive measurement.
We did not observe baclofen-induced increases in the
left dlPFC at rest. Evidence for functional heterogeneity
between the right and left dlPFC indicates the right is in-
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volved in hierarchical evaluation, while the left is involved in the evaluation of possible outcomes [71]. Thus,
tonic orientation toward identifying potentially relevant
stimuli at rest [72], without the need to evaluate potential
outcomes, may have engaged the right dlPFC in our study.
Thus, lateralization should be examined in future work.
Baclofen’s effects did not extend to the VS in the current
study. This could be due to individual heterogeneity within our sample, including sex and/or genetic differences
[56,73], and the inclusion of non-SC vulnerable individuals, all of which we are underpowered to examine.
These null findings underscore the heterogeneity in response to baclofen, and the importance of differentiating
SC-vulnerable individuals from other treatment seekers.
To date, most studies of baclofen for SUDs are for AUD,
with equivocal results [74-76], perhaps partially because
potential heterogeneity in treatment response has not been
examined. To date, three AUD studies have included neuroimaging during alcohol cue exposure [21,22,24], with
modest samples and mixed findings, however, they all
emphasize (1) that baclofen’s mechanism of action may
be through blunting cue reactivity and that (2) more work
is needed to understand this mechanism. Logge et al. particularly showed a dose-response effect such that a higher
dose of baclofen (75 mg/day) reduced heavy drinking
days compared to a lower dose (30 mg/day), which also
warrants consideration in future studies.
Additional smoking-cessation and relapse-prevention
medications are necessary for smokers trying to quit, as
the most commonly-prescribed agent, varenicline, does
not help the majority of patients to whom it is prescribed
[17,77]. Our group previously showed that the mechanism
by which varenicline reduces SC-reactivity is through an
increase in resting lateral OFC activation, which predicts
a decrease in SC-response in the medial OFC and ventral
striatum [26]. Contrasted with the regions affected by baclofen in this study, this differential neural response to varenicline suggests that the medications have different
mechanisms of action. Notably, baclofen, but not varenicline patients show a reduction in avInsula response to
smoking cues, and the avInsula is well-established hub of
interoception and craving [11,66,68]. In this vein, one
might speculate that varenicline’s limited effectiveness
may be because it does not directly block SC-reactivity: in
all previous varenicline studies examining SC-reactivity,
participants continued to smoke during treatment, before

assessment [26,78,79]. Perhaps the repeated blockade of
nicotine reward while smoking extinguishes conditioned
associations between the cues and cigarettes. Thus, as
Brandon and colleagues explicitly suggest, the observed
blockade of SC-induced craving could occur through
temporary SC-reward extinction [78]. Thus, varenicline’s
action to block reinforcement suggests it may be more
helpful for abstinence initiation in those whose vulnerabilities include avoidance of withdrawal and reward reinforcement [16], while baclofen may act as a relapseprevention agent in a cue-vulnerable subgroup, abstinent
at treatment initiation. This previously unaddressed emphasis on the potential use of baclofen for relapse-prevention rather than abstinence-initiation could partially
explain the discordant literature. As such, future studies
may find it useful to design studies that explicitly test the
usefulness of medications in abstinence-initiation and/or
relapse prevention to address individual vulnerabilities.
Baclofen has several inherent advantages for use as a
medication for smoking cessation. It is currently approved
for muscle spasticity by the United States Food and Drug
Administration [80], has a history of safety, is not abused,
and its generally benign adverse effects, when present, are
well-documented [81]. It is available in generic form and
is cost-effective. Its short half-life (4 hours) suits its use as a
relapse prevention medication on an as-needed basis: as
SCs are often context-dependent (e.g., being surrounded
by smokers at an event), an individual could take baclofen
prospectively, on an as-needed basis. Thus, baclofen is affordable and carries minimal risk, with an acute mechanism of action precluding the need for daily dosage.
Although baclofen’s effectiveness as a smoking cessation
aid was not tested here, it has shown promise in the few
placebo-controlled studies that have tested it. In a paradigm similar to the current study, using the same dose of
baclofen and setting the Quit Date to occur after 3 weeks
of study participation, baclofen reduced CPD [82]. In another study conducted in alcohol dependent smokers
seeking treatment for both, baclofen increased the number of days of abstinence of co-use [83]. While both of
these preliminary studies show proof of concept for further clinical examination in treatment-seeking cigarette
smokers baclofen’s efficacy has been challenged [76]. An
additional factor that may underlie the mixed therapeutic
profile of baclofen is individual response to medication.
While some studies show that low doses (~30 mg per day)
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are effective other studies show a dose response effect
with higher doses showing more effectiveness [22]. Marsot
et al. [84] recently identified a potential mitigating factor
that may provide some insight. In this pharmacokinetic
study the plasma concentration of baclofen showed
marked interpatient variability that remained unexplained
by a multitude of potential confounding factors.

Limitations and Future Directions
Although this study is strengthened by its within-subjects,
placebo-controlled, longitudinal design, it has limitations.
First, the modest sample size precludes our ability to examine heterogeneity in response to SCs or to baclofen that
may be introduced by additional factors such as individual pharmacokinetics [84] that might be affected by
sex, genetics, and hormonal variability [40,73]. Further,
to heighten homogeneity in brain response, a particular
design feature was to minimize changes in smoking behavior across participants; participants were asked to
‘smoke as usual’ until after the on-medication testing day
and smoked to satiety immediately before both test days,
which precluded the ability to study its potential effectiveness as a relapse prevention agent. Despite this, the literature to date indicates that baclofen does not block reinforcement while smoking, but rather influences reward
circuitry [20,85]. Nonetheless future studies should examine baclofen’s ability to block SC-reactivity explicitly
in abstinent smokers.
Conclusions
To date, the majority of smokers remain unaided by first
line available smoking cessation medications that act to
mitigate withdrawal and block reinforcement. As SC reactivity is a known relapse predictor, additional treatment
strategies that specifically target SC reactivity are crucial.
Our results suggest that the GABA-B agonist, baclofen,
mitigates the enhanced reward response to SCs, and that
this occurs through an increase in tonic activation of the
dlPFC, an executive control region. This mechanism is
congruent with the theory gaining recognition in the field,
that strengthening tonic executive functioning facilitates
recovery from SUDs. Finally, the variable effectiveness of
baclofen for SUDs documented to date may actually indicate a difference in cue-vulnerability vs. reward-sensitivity
in treatment-seeking individuals. Thus, baclofen may be
most effective in facilitating relapse prevention in cue vul-

nerable smokers who have already quit.
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